For instance, hypermethylation of CpG islands within the B4GALT1 promoter may contribute to transcriptional repression and reduced B4GALT1 expression, leading to altered glycosylation profiles associated with tumor progression and therapeutic resistance. This evidence concerns the gene B4GALT1 and neoplasm.